Bisphosphonates Might Get Limits On Treatment Duration Following Label Change
This article was originally published in The Pink Sheet Daily
Executive Summary
Accumulating data on femur fractures lead FDA to consider telling physicians to take patients off the drug at least temporarily when bone mineral density targets are reached.